Bioresource Engineering Division, RIKEN BioResource Research Center, Ibaraki, Japan.
Laboratory for Chromosome Segregation, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan.
EMBO Rep. 2022 Jul 5;23(7):e54992. doi: 10.15252/embr.202254992. Epub 2022 May 19.
Microinjection of spermatozoa or spermatids into oocytes is a major choice for infertility treatment. However, the use of premeiotic spermatocytes has never been considered because of its technical problems. Here, we show that the efficiency of spermatocyte injection in mice can be improved greatly by reducing the size of the recipient oocytes. Live imaging showed that the underlying mechanism involves reduced premature separation of the spermatocyte's meiotic chromosomes, which produced much greater (19% vs. 1%) birth rates in smaller oocytes. Application of this technique to spermatocyte arrest caused by STX2 deficiency, an azoospermia factor also found in humans, resulted in the production of live offspring. Thus, the microinjection of primary spermatocytes into oocytes may be a potential treatment for overcoming a form of nonobstructive azoospermia caused by meiotic failure.
将精子或精原细胞微注射到卵母细胞中是治疗不孕的主要选择。然而,由于技术问题,从未考虑使用减数分裂前期精母细胞。在这里,我们表明通过减小受体卵母细胞的大小,可以大大提高精母细胞注射的效率。活细胞成像显示,其潜在的机制涉及减数分裂染色体过早分离的减少,这在较小的卵母细胞中产生了更高的出生率(19%对 1%)。将该技术应用于由 STX2 缺乏引起的精母细胞阻滞,这也是人类中一种无精子症因子,导致了活后代的产生。因此,将初级精母细胞微注射到卵母细胞中可能是治疗因减数分裂失败导致的某种非梗阻性无精子症的潜在方法。